The Economist Intelligence Unit - HCV Change Makers 2017 programme acknowledges HCV innovators doing exemplary work in multi-stakeholder approaches, screening and technology. In 2016 two Australians were included and this year there are three.
While prevention and treatment of hepatitis C (HCV) have traditionally been fragmented, multi-sector collaboration to address health gaps is becoming increasingly common. The success of Australia’s response to hepatitis C has been underpinned by a partnership approach across the government, community, clinical and research sectors.
For 2017 Professor Greg Dore and Helen Tyrrell have been recognised for their efforts in multi-stakeholder approaches. Prof. Dore heads up the Viral Hepatitis Clinical Research Programme at the Kirby Institute and is an Infectious Diseases Physician at St Vincent’s Hospital in Sydney. Helen Tyrrell is the CEO of Hepatitis Australia, the peak community hepatitis organisation in Australia with a mission to lead an effective national community response to hepatitis B and hepatitis C in Australia.
Australia has also been recognised in the area of technology. This looks at the role of technology in delivering information that supports prevention and connectedness to care. The CEO of Hepatitis Victoria, Melanie Eagle has been acknowledged for raising awareness of Hepatitis C amongst healthcare practitioners with online education tools, and amongst patients with a mobile app to assess liver health information.
Hepatitis Australia would like to acknowledge and congratulate all eighteen HCV Change Makers for 2017. Their efforts demonstrate that working toward the elimination of hepatitis C requires a variety of stakeholders to be involved.
To find out more and see who else has been recognised go to http://pathtozero.eiu.com/2017-hcv-change-makers/